Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trial
A Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The startup, Windward Bio, has raised a ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · CN
- [HEALTH] Who writes the pandemic? State power, individual subjectivity, and the history of the present in China's COVID-19 respon
- [ENERGY] EU bans funding for Chinese solar tech
- [FINANCE] Bessent urges China to step up diplomacy on Iran ahead of Trump-Xi summit
- [ENERGY] China Orders Refiners to Ignore U.S. Sanctions on Key Iranian Oil Buyers - Crude Oil Prices Today | OilPrice.com
- [FINANCE] China Orders Refiners to Ignore U.S. Sanctions on Key Iranian Oil Buyers
- [CONFLICT] UCB to acquire maker of antibody treatments for autoimmune diseases